CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 11 enrolled
Drug / intervention
siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03087591
NCT03087591Phase 1Completed

Safety and Immunologic Activity of Multiple Infusions of APN401

Wake Forest University Health Sciences·interventional·Posted Mar 22, 2017·Updated Oct 10, 2024

In Brief

A Phase 1 clinical trial evaluating Laboratory Biomarker Analysis and siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401 for Metastatic Malignant Neoplasm in the Brain and 11 related conditions. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back. APN401 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 22, 2017
Enrollment StartApr 28, 2017
Primary CompletionJul 31, 2019
Study CompletionDec 8, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.3 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401biological

Given IV